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gene on cardiovascular mortality, Tanus-Santos et al. recalled that the
former SNP alters the gene responsiveness to statins: statins would
up-regulate eNOS expression (2) more potently in -786C homozy-
gous (3) and therefore, these subjects would generate more NO while
on statins than subjects with the other genotypes. Accordingly,
atorvastatin increased NO availability and reduced inflammatory
marker concentrations in CC, but not in TT healthy men (4).
However, we found no significant interaction between statin treat-
ment and the T-786C SNP affecting cardiovascular mortality (1).
Moreover, only a minority of our patients were on statins (5);
therefore, this mechanistic explanation is unlikely.
As with Tanus-Santos et al., we also found that the T-786C SNP
did not affect nitrite/nitrate levels; however, functional data (6)
indicate that the T-786C SNP affects NO bioactivity by altering the
gene responsiveness to shear stress (7). Thus, the “Janus” nature of
eNOS might reveal itself under conditions of oxidant stress, leading to
decreased plaque stability and cardiovascular events (1).
Antoniades et al. raised another appealing hypothesis: an
interaction of the 786T with the 894T allele constituting the
894T/786T haplotype might lower eNOS expression and increase
susceptibility of eNOS to proteolytic cleavage, resulting into
transiently increased oxidant stress and inflammatory status during
acute conditions (8). However, the G894T SNP lies within a loop
on the external surface of eNOS and does not make contact with
either the active site of the enzyme, or the dymerization interface,
suggesting that, if functional, this SNP could act by a mechanism
independent of eNOS catalysis. Moreover, the increased suscep-
tibility to cleavage of the Asp298-encoded eNOS enzyme has been
shown to be artifactual (reviewed by Casas et al.) (9). Therefore,
whether the 894T allele bears functional consequences remains
controversial. Nonetheless, the linkage disequilibrium of the
T-786C and G894T SNP (1) can explain the association of the
latter SNP with coronary heart disease (CHD), as we pointed out.
Antoniades et al. stated that an increased risk of CHD (odds ratio
[OR]  1.31) for the 894T allele carriers was reported; however, the
excess risk deriving from meta-analysis of cross-sectional association
studies, which are prone to stratification biases, should be viewed
cautiously. In fact, a much larger meta-analysis led to a markedly
reduced estimate of risk (OR  1.17) (9).
Consistent with prospective study results in high-risk patients
(1,10), we found no evidence for a prognostic effect of the 894T
allele. Thus, even if the 894T homozygosity would imply a blunted
NO production and/or higher levels of oxidized low-density
lipoprotein and proinflammatory cytokines during acute coronary
events, overall prospective cohort studies show no prognostic effect
in high-risk patients.
Finally, although underlying the fact that intriguing results such
as ours are crucial for generating novel hypotheses, we agree that
the elucidation of the complex interplay between the eNOS gene
haplotypes and environmental factors deserves further research.
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Noncardiac Findings in
Computed Tomography
Coronary Angiography
The report by Onuma et al. (1) on noncardiac findings in
multidetector computed tomography (MDCT) and the accompa-
nying editorial comment by Rumberger (2) raise interesting issues.
Onuma et al. (1) found that approximately 23% of 503 patients
undergoing CT coronary angiography demonstrated significant
noncardiac pathology requiring follow-up. This included 2 lung
and 2 breast malignancies. Similarly, Baum et al. (3) have recently
reported a high prevalence of extracardiac disease, including
malignancies, among over a thousand patients undergoing
MDCT.
Rumberger (2) suggests medico-legal and moral imperatives to
seek noncardiac pathology. The patient’s entire chest and upper
abdomen have been irradiated, after all, and the imaging data are
there awaiting reconstruction. Although this approach seems very
reasonable, I believe we need to keep an open mind, recognizing
the absence of hard evidence that the pursuit of extracardiac
pathology leads to overall improved patient outcomes. Much of the
noncardiac pathology, such as liver and renal cysts, is relatively
unimportant and probably unrelated to the symptom of chest pain.
With regard to more serious pathology, several questions arise:
When found, are the newly discovered malignancies curable or
amenable to treatment that prolongs life or improves quality of
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life? What percentage of patients requires repetitive imaging scans
and further irradiation, and at what risk? What is the morbidity
and mortality attendant to the biopsies and surgery for lesions that
ultimately turn out to be benign?
I believe we are at a crossroads where additional input from
epidemiologists, oncologists, radiologists, cardiologists, and others
is required to delineate further how far to widen or restrict the
MDCT “field of view.” Because large randomized prospective
studies are unlikely in this regard, perhaps mathematical models of
outcomes and costs could be formulated.
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Reply
Dr. Fleet raises important questions, and there is legitimate
concern that computed tomography (CT) scan “incidentalomas”
can result in unnecessary or inappropriate testing at the expense of
the insurance system and/or risk to the patient (1,2).
The main issue regarding cardiac CT is, of course, coincident
imaging of the adjacent lungs. Although lung cancer is the number
one cause of cancer-related deaths in all men and women in
America, the finding of variable size “lung nodules” is much more
common than true malignant disease. Dr. Fleet asks: “When
found, are the newly discovered malignancies curable or amenable
to treatment that prolongs life or improves quality of life?” We may
never have a complete answer to this inquiry. However, the overall
survival rates for lung cancer are dismal, and the most recent report
from the ELCAP (Early Lung Cancer Action Program) study (3)
may provide a partial response. Henschke and colleagues (3) did
screening lung scans in adults over 40 years old with either a
history of cigarette smoking, an occupational exposure risk, or
significant exposure to second-hand smoke, and they found that
stage I lung cancers discovered (and treated) resulted in a projected
80% 10-year survival. These subjects are, coincidentally, at greatest
risk for atherosclerotic heart disease. Importantly, however, lung
cancer was found in only 484 (1.5%) of 31,567 screened individuals.
Dr. Fleet asks, “What is the morbidity and mortality attendant
to the biopsies and surgery for lesions that ultimately turn out to be
benign?” This is a rhetorical question as we do not have this
information; however, in most instances biopsies are unnecessary,
and follow-up low-dose CT scanning may be the only suggested
consequence. In medicine we tend to “pass the buck” when it
comes to test results that are unanticipated, and the best way to
reduce unnecessary follow-up testing or procedures is physician
education. There are guidelines published by the ELCAP inves-
tigators (4), which prescribe follow-up on the basis of lung nodule
dimensions. More recently the Fleischner Society (5) described the
workup of small pulmonary nodules incorporating smoking history
as part of the clinical algorithm.
I agree that we are at a crossroad to define the clinical impact of
diagnostic CT angiography and “extravascular” pathology, regard-
less of whether it involves the heart/chest, neck, abdomen, or
periphery. The issue clearly extends beyond traditional single-
specialty medicine. Recently, a published commentary (6) ad-
dressed training in advanced cardiovascular imaging, stating that
“specific interpretation of the extra-cardiac fields should be per-
formed. . . . Regarding the cardiovascular medicine specialist per-
forming a cardiac CT, the American College of Cardiology
recognizes and endorses education and training of such individuals
in the recognition of incidental scan findings in support of quality
imaging care of patients with cardiovascular disease. . . . To this
end, it is felt that Level 2 and Level 3 training should include
review of all cardiac CT for noncardiac findings.”
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Reply
We thank Dr. Fleet for his interest in our study (1) and appreciate
his comments. We agree with Dr. Fleet as to the necessity of
further evidence to establish the clinical significance of noncardiac
analysis in cardiac multidetector computed tomography (MDCT).
Our study lacks long-term clinical follow-up to discuss clinical
outcomes. In addition, we did not discuss cost because the actual
cost of additional follow-up, including surgery, biopsy, and imag-
ing, varies among countries and institutions. As clinical results and
costs could be different depending on how referring physicians
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